The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relationship of hypoxia signature with variant subgroup of clear cell renal cell carcinoma (ccRCC) and its association with clinical activity on tivozanib hydrochloride.
Murray Owen Robinson
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Bin Feng
Employment or Leadership Position - AVEO
Richard Nicoletti
Employment or Leadership Position - AVEO
Anna Berkenblit
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Andrew Louis Strahs
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Brooke Esteves
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
Timothy Eisen
Consultant or Advisory Role - Astellas Pharma (U); AVEO (U)
Stock Ownership - AstraZeneca
Research Funding - Bayer; GlaxoSmithKline; Pfizer
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - AVEO; GlaxoSmithKline; Pfizer